Driving Innovation
Merck Opens Application Phase for Next Accelerator
Merck announced that it has opened the next round of applications for startup companies to participate in the global Merck Accelerator program. Startups can choose to participate in one of the two programs, either at the company’s Innovation Center at global headquarters in Darmstadt or at its China Innovation Hub in Shanghai. Applications for both programs are open from now until August 25, 2019.
The Merck Accelerator with programs in Germany and in China connects startups to innovation projects of Merck and its three business sectors for co-development and sustainable business partnerships. During a three-month period, startups receive financial support of up to € 50,000 and benefit from in-depth coaching from a global network of over 50,000 experts, as well as mentoring from Merck senior management, coaching sessions and visibility by attending inspirational and renowned events in the startup ecosystem.
In Darmstadt, the chosen startups will have access to the modern workspace at the futuristic Merck Innovation Center with prototyping facilities in the Makerspace. In China, startups will have access to the local Merck network and mixed sites such as Guangzhou, Beijing and Shanghai with different business focus and ecosystems.
Besides the core areas of Merck research in Healthcare, Life Science and Performance Materials, the main focus of the Merck Accelerator is to partner with startups in the company’s innovation fields:
Biosensing & Interfaces: technologies to interface between the biological and digital world
Liquid Biopsy Technologies: solutions to overcome challenges in the liquid biopsy workflow
Clean Meat: enabling technology required to produce clean meat (specifically for the headquarters program at the Innovation Center)
AI-enabled health solutions that include AI solutions for diagnosis rate improvement and precision medicine; AI-enabled drug R&D; Digital therapeutics (specifically for the program in China)
“We have a lot of experience in partnering with startups. To make collaboration happen, we ensure startups the right connections within Merck,” said Michael Gamber, Head of Merck Innovation Center. “The last intake of the Merck Accelerator at the Innovation Center was incredibly successful and 90% of the startups are either collaborating or in negotiations to partner with us.”
So far, 57 startups have already participated in the Merck Accelerator program since the first intake in 2015. Merck is currently looking for up to 12 startups to participate in the program in Darmstadt and up to six startups for its China Innovation Hub.
The Accelerator programs will simultaneously take place from mid-January to April 2020 at the Merck Innovation Center in Darmstadt and at the China Innovation Hub. Right after each program, selected startups will also have the opportunity to extend their stay either in China or in Darmstadt. Applications for both programs are open from now until August 25, 2019.
For more information, please visit this website:https://www.merckgroup.com/en/research/innovation-center/accelerator.html
Source: Merck
Das könnte Sie auch interessieren
Acquisition enhances bioprocess portfolio
Merck acquires Resolution Spectra Systems
Merck enhances its bioprocess portfolio through the acquisition of Resolution Spectra Systems. The company based in France offers Raman spectroscopy analysis through its GMP-ready instrumentation and software.
mehr...Eppendorf posts a strong fiscal year 2019
For the Hamburg-based Eppendorf Group, a globally active life science company, 2019 proved to be a very good fiscal year.
mehr...Thermo Fisher Scientific to Acquire Qiagen
Thermo Fisher Scientific Inc. and Qiagen N.V. announced that their boards of directors, as well as the managing board of Qiagen N.V., have unanimously approved Thermo Fisher’s proposal to acquire Qiagen for €39 per share in cash.
mehr...Agilent to Acquire Biotek
Agilent Technologies Inc. (NYSE: A) announced it has signed a definitive agreement to acquire privately-owned BioTek Instruments for $1.165 billion. With anticipated tax benefits for Agilent, the net purchase price is expected to be approximately...
mehr...Stefan Oschmann übergibt 2021 den Vorsitz der Geschäftsleitung an Belén Garijo
Im Jahr 2021 wird Stefan Oschmann den Vorsitz der Geschäftsleitung von Merck an Belén Garijo übergeben. Weiterhin werden neue Mitglieder der Geschäftsleitung die Unternehmensbereiche Healthcare und Life Science verantworten.
mehr...Ausbau der Herstellungskapazitäten
Merck investiert in Antikörper-Wirkstoff-Konjugat-Herstellung
Merck hat eine Investition in Höhe von 59 Mio. Euro für den Ausbau seiner Herstellungskapazitäten für hochaktive Wirkstoffe (HPAPI) und Antikörper-Wirkstoff-Konjugate (ADCs) in den USA bekannt gegeben.
mehr...Sartorius renews its brand focus
Sartorius has revised its brand look today and presents a new logo, new colors and a new brand promise: Simplifying Progress.
mehr...Monitoring organs and cells in living fruit fly larvae
Scientists have developed a method to study processes taking place in the cells of a living fruit fly larva.
mehr...Melting reveals drug targets in a living...
EMBL scientists identify drug targets in blood and organs
Developing new medicines and understanding how they target specific organs often gives a crucial advantage in the fight against human diseases. An international team led by researchers at the European Molecular Biology Laboratory and Cellzome, a GSK...
mehr...